Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Molecular Profile | ERBB3 V104L |
| Therapy | Irinotecan + Pyrotinib |
| Indication/Tumor Type | gastric adenocarcinoma |
| Response Type | predicted - sensitive |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| ERBB3 V104L | gastric adenocarcinoma | predicted - sensitive | Irinotecan + Pyrotinib | Case Reports/Case Series | Actionable | In a clinical case study, combination treatment Camptosar (irinotecan) and Pyrotinib in a patient with metastatic gastric adenocarcinoma harboring ERBB3 V104L, who had relapsed on prior treatment with chemotherapy, led to stable disease and a progression-free survival of 7.6 months (PMID: 33500629). | 33500629 |
| PubMed Id | Reference Title | Details |
|---|---|---|
| (33500629) | Gastric Cancer Harboring an ERBB3 Mutation Treated with a Pyrotinib-Irinotecan Combo: A Case Study. | Full reference... |